TVTX
Travere Therapeutics, Inc.Company with tickers: TVTX
CIK
1438533
CUSIP
89422G107
Shares Outstanding
92,992,905
Website
https://travere.com
Investor Relations
https://ir.travere.com/overview/default.aspx
13F Activity (30d)
23 filings
3 filers
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Jula Inrig, M.D. | Executive Vice President, Head of Research & Development and Chief Medical Officer | Appointed | 2026-06-16 |